Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
August 24, 2020 08:00 ET
|
Biocept, Inc.
SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information...
Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
August 20, 2020 08:30 ET
|
Biocept, Inc.
SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information...
Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
August 19, 2020 08:00 ET
|
Biocept, Inc.
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable...
Biocept Reports First Quarter 2015 Financial Results
May 12, 2015 16:05 ET
|
Biocept, Inc.
Announces Increased Revenues and Strong Year-over-Year Growth in Test Volume
Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc....
Biocept, Inc. Schedules Webcast and Conference Call for First Quarter 2015 Financial Results
May 04, 2015 16:15 ET
|
Biocept, Inc.
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating...
Biocept Expands Oncology Diagnostic Portfolio With Launch of c-MET Biomarker
May 04, 2015 08:30 ET
|
Biocept, Inc.
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating...
Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center
March 24, 2015 08:30 ET
|
Biocept, Inc.
SAN DIEGO, March 24, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating...
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
March 10, 2015 08:30 ET
|
Biocept, Inc.
SAN DIEGO, March 10, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating...
Biocept Reports Fourth Quarter 2014 Financial Results
March 09, 2015 16:05 ET
|
Biocept, Inc.
SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating...
Next Generation Sequencing Veteran Joins Biocept
March 05, 2015 08:30 ET
|
Biocept, Inc.
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA)...